Roquinimex

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Roquinimex
Accession Number
DB11366
Type
Small Molecule
Groups
Investigational
Description

Roquinimex (Linomide) is a quinoline derivative immunostimulant which increases NK cell activity and macrophage cytotoxicity. It also inhibits angiogenesis and reduces the secretion of TNF alpha.

Structure
Thumb
Synonyms
  • Linomide
External IDs
FCF 89 / FCF-89 / LS 2616
Categories
UNII
372T2944C0
CAS number
84088-42-6
Weight
Average: 308.337
Monoisotopic: 308.116092383
Chemical Formula
C18H16N2O3
InChI Key
SGOOQMRIPALTEL-UHFFFAOYSA-N
InChI
InChI=1S/C18H16N2O3/c1-19(12-8-4-3-5-9-12)17(22)15-16(21)13-10-6-7-11-14(13)20(2)18(15)23/h3-11,21H,1-2H3
IUPAC Name
4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide
SMILES
CN(C(=O)C1=C(O)C2=C(C=CC=C2)N(C)C1=O)C1=CC=CC=C1

Pharmacology

Indication

Investigated as a treatment for some cancers (including as adjuvant therapy after bone marrow transplantation in acute leukemia) and autoimmune diseases, such as multiple sclerosis and recent-onset type I diabetes.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Roquinimex.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Roquinimex.Experimental
BevacizumabBevacizumab may increase the cardiotoxic activities of Roquinimex.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Roquinimex.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Roquinimex.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Roquinimex.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Roquinimex.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Roquinimex.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Roquinimex.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Roquinimex.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Roquinimex.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Roquinimex.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Roquinimex.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Roquinimex.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Roquinimex.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Roquinimex.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Roquinimex.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Roquinimex.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Roquinimex.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

E. Eriksoo et al., EP 59698; eidem, U.S. Patent 4,738,971 (1982, 1988 both to AB Leo).

General References
Not Available
External Links
PubChem Compound
54676478
PubChem Substance
347827974
ChemSpider
10619239
ChEBI
92056
ChEMBL
CHEMBL11672
Wikipedia
Roquinimex
ATC Codes
L03AX02 — Roquinimex

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.123 mg/mLALOGPS
logP1.57ALOGPS
logP1.59ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)6.03ChemAxon
pKa (Strongest Basic)-2.4ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area60.85 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity87.75 m3·mol-1ChemAxon
Polarizability31.61 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as aromatic anilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with an aromatic group. They have the general structure RNC(=O)R', where R= benzene, and R = aryl group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Anilides
Direct Parent
Aromatic anilides
Alternative Parents
Quinoline-3-carboxamides / Hydroquinolones / Hydroxyquinolines / Hydroquinolines / Pyridinecarboxylic acids and derivatives / Hydroxypyridines / Pyridinones / Tertiary carboxylic acid amides / Vinylogous acids / Vinylogous amides
show 8 more
Substituents
Aromatic anilide / Quinoline-3-carboxamide / Dihydroquinolone / Hydroxyquinoline / Dihydroquinoline / Quinoline / Pyridine carboxylic acid or derivatives / Hydroxypyridine / Pyridinone / Pyridine
show 17 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on February 10, 2016 15:31 / Updated on November 09, 2017 04:53